RU2021112503A - Поливалентная вакцина против м. hyo и её применение - Google Patents
Поливалентная вакцина против м. hyo и её применение Download PDFInfo
- Publication number
- RU2021112503A RU2021112503A RU2021112503A RU2021112503A RU2021112503A RU 2021112503 A RU2021112503 A RU 2021112503A RU 2021112503 A RU2021112503 A RU 2021112503A RU 2021112503 A RU2021112503 A RU 2021112503A RU 2021112503 A RU2021112503 A RU 2021112503A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- prrsv
- killed
- pigs
- administration
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims 18
- 238000000034 method Methods 0.000 claims 9
- 241000282887 Suidae Species 0.000 claims 8
- 238000002255 vaccination Methods 0.000 claims 4
- 241001673669 Porcine circovirus 2 Species 0.000 claims 3
- 241000282898 Sus scrofa Species 0.000 claims 2
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 claims 1
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 claims 1
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 claims 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 1
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 claims 1
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 claims 1
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 claims 1
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 claims 1
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 claims 1
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 claims 1
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 claims 1
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 claims 1
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 claims 1
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 claims 1
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 claims 1
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 claims 1
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 claims 1
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 claims 1
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 claims 1
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 claims 1
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 claims 1
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 claims 1
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 claims 1
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 claims 1
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 claims 1
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 claims 1
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 claims 1
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 claims 1
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 claims 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229960000380 propiolactone Drugs 0.000 claims 1
- 208000012153 swine disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Способ вакцинации свиней от болезни свиней, включающий:
введение свиньям антигена Mycoplasma hyopneumoniae (M. hyo), антигена убитого вируса репродуктивного и респираторного синдрома свиней (PRRSV) и антигена модифицированного живого PRRSV.
2. Способ по п. 1, который дополнительно включает введение свиньям антигена свиного цирковируса типа 2 (PCV2).
3. Способ по п. 1, в котором введение антигена M. hyo, антигена убитого PRRSV и антигена модифицированного живого PRRSV увеличивает способность свиней набирать массу по сравнению с введением только антигена убитого PRRSV и антигена модифицированного живого PRRSV.
4. Способ по п. 1, в котором введение антигена M. hyo, антигена убитого PRRSV и антигена модифицированного живого PRRSV снижает риск смерти свиней по сравнению с введением только антигена убитого PRRSV и антигена модифицированного живого PRRSV.
5. Способ по п. 1, в котором свиней вакцинируют в соответствии с режимом вакцинации «прайм-буст».
6. Способ вакцинации свиней против болезни свиней в соответствии с режимом вакцинации «прайм-буст», включающий:
введение свиньям антигена M. hyo, антигена PCV2 и первого антигена PRRSV; и затем
введение свиньям второго антигена вируса PRRSV.
7. Способ по п. 6, в котором первый антиген PRRSV представляет собой модифицированный живой вирус PRRSV, а второй антиген PRRSV представляет собой инактивированный вирус PRRSV.
8. Способ по п. 1, в котором антиген убитого PRRSV включает полинуклеотид, кодирующий белок ORF5, имеющий, по меньшей мере, 95% идентичности последовательности, по меньшей мере, с одной из SEQ ID NO: 2-9.
9. Способ по п. 1, в котором антиген убитого PRRSV был убит с использованием бинарного этиленимина, формальдегида, бетапропиолактона или любых их комбинаций.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562272017P | 2015-12-28 | 2015-12-28 | |
| US62/272,017 | 2015-12-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018127403A Division RU2018127403A (ru) | 2015-12-28 | 2016-12-14 | Поливалентная вакцина против hyo и ее применение |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2021112503A true RU2021112503A (ru) | 2021-05-05 |
Family
ID=57681803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018127403A RU2018127403A (ru) | 2015-12-28 | 2016-12-14 | Поливалентная вакцина против hyo и ее применение |
| RU2021112503A RU2021112503A (ru) | 2015-12-28 | 2016-12-14 | Поливалентная вакцина против м. hyo и её применение |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018127403A RU2018127403A (ru) | 2015-12-28 | 2016-12-14 | Поливалентная вакцина против hyo и ее применение |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20170182141A1 (ru) |
| EP (1) | EP3397279A1 (ru) |
| JP (1) | JP6839714B2 (ru) |
| KR (1) | KR102166196B1 (ru) |
| CN (1) | CN108601824A (ru) |
| AU (1) | AU2016380864B2 (ru) |
| CA (1) | CA3009656A1 (ru) |
| MA (1) | MA43517A (ru) |
| MX (1) | MX2018007950A (ru) |
| MY (1) | MY191905A (ru) |
| NZ (1) | NZ743977A (ru) |
| PH (1) | PH12018501368A1 (ru) |
| RU (2) | RU2018127403A (ru) |
| SG (1) | SG11201805379QA (ru) |
| WO (1) | WO2017116698A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107753942A (zh) * | 2017-09-30 | 2018-03-06 | 天津瑞普生物技术股份有限公司 | 一种pcv2、prrsv、猪肺炎支原体三联灭活疫苗制备方法 |
| JP7510874B2 (ja) * | 2017-12-22 | 2024-07-04 | ヒプラ シエンティフィック エセ．エレ．ウ． | マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン |
| KR102228308B1 (ko) * | 2018-12-19 | 2021-03-16 | 주식회사 이노백 | 마이코플라즈마 폐렴 및 흉막폐렴 예방용 백신 조성물 |
| WO2021018806A1 (en) * | 2019-07-26 | 2021-02-04 | Ceva Sante Animale | Igg-depleted porcine serum and the uses thereof |
| KR102646305B1 (ko) * | 2021-03-04 | 2024-03-13 | 주식회사 이노백 | 돼지 마이코플라스마균 및 돼지 써코바이러스 감염 예방을 위한 다가 백신 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007222016A1 (en) * | 2006-03-03 | 2007-09-13 | Merial Limited | Mycoplasma hyopneumoniae vaccine |
| MX2008012972A (es) * | 2006-04-10 | 2009-01-16 | Intervet Int Bv | Vacuna contra sindrome respiratorio reproductivo porcino atenuado vivo de micoplasma. |
| AU2008343172B2 (en) * | 2007-12-21 | 2015-02-19 | Zoetis Services Llc | Methods and compositions for immunizing pigs against porcine circovirus |
| EP2242511A4 (en) * | 2008-01-23 | 2012-10-24 | Boehringer Ingelheim Vetmed | IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS |
| TWI627281B (zh) * | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物 |
| UA114504C2 (uk) * | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
| CA2879228C (en) * | 2012-07-17 | 2021-07-13 | Merial Limited | Attenuated swine influenza vaccines and methods of making and use thereof |
| CN104043118A (zh) * | 2013-03-11 | 2014-09-17 | 普莱柯生物工程股份有限公司 | 猪prrsv、猪肺炎支原体和pvc-2抗原在制备疫苗中的应用 |
| CN105073130A (zh) * | 2013-03-15 | 2015-11-18 | 勃林格殷格翰动物保健公司 | 猪生殖与呼吸综合征病毒、组合物、疫苗及使用方法 |
-
2016
- 2016-12-14 US US15/378,165 patent/US20170182141A1/en not_active Abandoned
- 2016-12-14 NZ NZ743977A patent/NZ743977A/en not_active IP Right Cessation
- 2016-12-14 KR KR1020187021708A patent/KR102166196B1/ko not_active Expired - Fee Related
- 2016-12-14 RU RU2018127403A patent/RU2018127403A/ru unknown
- 2016-12-14 MY MYPI2018001113A patent/MY191905A/en unknown
- 2016-12-14 JP JP2018534139A patent/JP6839714B2/ja not_active Expired - Fee Related
- 2016-12-14 SG SG11201805379QA patent/SG11201805379QA/en unknown
- 2016-12-14 WO PCT/US2016/066481 patent/WO2017116698A1/en not_active Ceased
- 2016-12-14 CN CN201680080280.9A patent/CN108601824A/zh active Pending
- 2016-12-14 EP EP16820125.9A patent/EP3397279A1/en active Pending
- 2016-12-14 RU RU2021112503A patent/RU2021112503A/ru unknown
- 2016-12-14 MX MX2018007950A patent/MX2018007950A/es unknown
- 2016-12-14 AU AU2016380864A patent/AU2016380864B2/en not_active Ceased
- 2016-12-14 CA CA3009656A patent/CA3009656A1/en not_active Abandoned
- 2016-12-14 MA MA043517A patent/MA43517A/fr unknown
-
2018
- 2018-06-25 PH PH12018501368A patent/PH12018501368A1/en unknown
-
2023
- 2023-06-28 US US18/343,081 patent/US20240024448A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ743977A (en) | 2020-01-31 |
| CN108601824A (zh) | 2018-09-28 |
| US20170182141A1 (en) | 2017-06-29 |
| CA3009656A1 (en) | 2017-07-06 |
| SG11201805379QA (en) | 2018-07-30 |
| MX2018007950A (es) | 2018-09-21 |
| KR20180096786A (ko) | 2018-08-29 |
| RU2018127403A (ru) | 2020-01-30 |
| PH12018501368A1 (en) | 2019-02-18 |
| AU2016380864A1 (en) | 2018-07-19 |
| US20240024448A1 (en) | 2024-01-25 |
| JP6839714B2 (ja) | 2021-03-10 |
| AU2016380864B2 (en) | 2019-10-31 |
| RU2018127403A3 (ru) | 2020-01-30 |
| MA43517A (fr) | 2018-11-07 |
| KR102166196B1 (ko) | 2020-10-15 |
| JP2019501180A (ja) | 2019-01-17 |
| EP3397279A1 (en) | 2018-11-07 |
| WO2017116698A1 (en) | 2017-07-06 |
| MY191905A (en) | 2022-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Intranasal vaccine: Factors to consider in research and development | |
| RU2021112503A (ru) | Поливалентная вакцина против м. hyo и её применение | |
| US11000585B2 (en) | Composition comprising antigens and a mucosal adjuvant and a method for using | |
| FI3355915T3 (fi) | Koirien parvoviruksen (CPV) viruksen kaltaisten hiukkasten (VLP) rokotteet ja niiden käytöt | |
| RU2017124186A (ru) | Противоящурная вакцина | |
| RU2018137034A (ru) | Комбинированная вакцина против вируса pcv2 и инфекции mycoplasma hyopneumoniae | |
| JP2019509300A5 (ru) | ||
| Lin et al. | Long-term protection elicited by an inactivated vaccine supplemented with a water-based adjuvant against infectious hematopoietic necrosis virus in rainbow trout (Oncorhynchus mykiss) | |
| JP6484241B2 (ja) | ＰＲＲＳおよびローソニア・イントラセルラリス（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）に対するブタワクチン | |
| RU2019136252A (ru) | Вакцины, содержащие патогены свиней, для ассоциированного несмешанного применения | |
| JP2019512518A5 (ru) | ||
| RU2018137033A (ru) | Вакцина для внутрикожного применения против инфекции вируса pcv2 и prrs | |
| CO5721019A2 (es) | Aislados y vacunas antigenicos de virus de bursitis infecciosa | |
| Anusha et al. | Strategies and Techniques for Enhancing Fish Health and Averting Disease Outbreaks in Aquaculture Settings through the Use of Vaccination: A Review. | |
| TH1801005741A (th) | วัคซีนสำหรับการประยุกต์ใช้ภายในผิวหนังเพื่อต่อต้านการติดเชื้อไวรัสpcv2และprrs | |
| Bertrand et al. | Flexible adjuvants for combined live and inactivated swine vaccines. | |
| Monika et al. | Homologous and heterologous antibody response following foot-and-mouth disease outbreak in vaccinated cattle | |
| Warner et al. | Control of Ornithobacterium rhinotracheale in poultry | |
| RU2018137036A (ru) | Комбинированная вакцина против инфекции вирусами pcv2 и prrs, содержащая альбумин | |
| RU2020142931A (ru) | Вакцинация против цирковирусов свиней | |
| Alishahi et al. | Serum antibody response of rainbow trout, Oncorhynchus mykiss to two species of pathogenic bacteria; Streptococcus iniae and Lactococcus garviae | |
| RU2476237C1 (ru) | Способ повышения эффективности вакцинации лошадей | |
| JP2019509302A5 (ru) | ||
| Haiwick et al. | Trivalent vaccine mixture protects against simultaneous challenge with M. hyopneumoniae, PCV2, and PRRS virus | |
| Cline et al. | A case report on the dynamics of PCVAD in a PCV2-vaccinated herd over time |